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Background: This cross-sectional, nested cohort study assessed Female Sexual Function Index (FSFI) scores in
postmenopausal women with breast cancer receiving primary chemotherapy.
Methods: The FSFI questionnaire was administered to 24 postmenopausal women one month after diagnosis
of breast cancer (post-diagnosis group) and one month after completion of the first cycle of primary
anthracyclin-based chemotherapy (post-chemotherapy group). Scores were compared to those of 24 healthy
postmenopausal women seeking routine gynecological care (control group). All patients were sexually active at
the time of enrollment. Mean age was 57.29 ± 11.82 years in the breast cancer group and 52.58 ± 7.19 years in
the control group.
Results: Scores in all domains of the FSFI instrument were significantly lower in the post-diagnosis group than in
controls (−41.3%, p < 0.001). A further major reduction in FSFI scores was evident on completion of one cycle of
primary chemotherapy (down 46.7% from post-diagnosis scores, p < 0.003), again in all domains. Six patients (25%)
ceased all sexual relations, in a significant change from baseline (p < 0.001). After one chemotherapy cycle, a further
five patients ceased sexual activity, for a total of 11 (45.8%) participants – a borderline significant difference
(p = 0.063).
Conclusion: The present study shows that female sexual function as assessed by the FSFI declines significantly at
two distinct points in time: upon diagnosis of breast cancer and after administration of systemic chemotherapy.
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Breast cancer is the second most common malignancy
worldwide, and most frequently affects women over the
age of 50 [1]. The disease is highly prevalent and inci-
dent in the Southern Region of Brazil. A total of 49,240
new cases of breast cancer are expected to have oc-
curred in Brazil in 2010, for an estimated risk of 49.5
cases per 100,000 women. Breast cancer is the second
most common malignancy in women (64.3 cases/
100,000 population), exceeded only by non-melanoma
skin cancers (87.4 cases/100,000), and is the most preva-
lent malignant neoplasm among women in the state of* Correspondence: jacc@orion.ufrgs.br
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distribution, and reproduction in any mediumRio Grande do Sul (81.6 cases/100,000). Fortunately, the
number of new cases and the number of deaths are in-
creasingly disproportionate as the population of breast
cancer survivors experiences significant growth. This en-
couraging finding is largely due to early detection and to
the therapeutic arsenal currently available [2,3].
Postmenopausal women experience reductions in es-
trogen levels and the classical symptoms of hot flashes,
vaginal dryness, and dyspareunia, which contribute to a
decline in sexual activity [4], also occurring on patients
treated for breast cancer [5]. The detection of sexual
dysfunction and poor sexual quality of life in women
treated for breast cancer is the subject of increasing re-
search interest. Unfortunately there is no clear relation-
ship linking treatments applied to breast cancer patients
and its direct effects on sexual dysfunction. Symptomstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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remains controversial on its origins, arising from intrin-
sic hormonal and/or psychological causes and can be
worsened by chemotherapy for example [1,6,7].
Many patients with sexual complaints are seen by breast
specialists and oncologists, all of which require specific at-
tention. Patient’s quality of life and sexuality issues should
be addressed in parallel with cancer treatment [3].
Female Sexual Function Index (FSFI) is a tool con-
sisted by a brief scale designed for assessment of sexual
functioning in women and was translated and validated
for use in Portuguese-speaking patients in Brazil [7-9].
Primary chemotherapy, also known as neoadjuvant
chemotherapy, is administered as first-line therapy be-
fore surgery. Its primary purpose is to reduce tumor size
or extent in order to provide improved local conditions
for surgery, often enabling conservative rather than rad-
ical procedures and, sometimes, even rendering inoper-
able tumors operable [10]. Initially restricted to patients
with locally advanced or inoperable disease, primary
chemotherapy has brought major advantages to the
treatment of breast cancer. As it is administered before
surgery or radiation, this model of treatment provides an
opportunity for observation of in vivo response to
chemotherapy.
The purpose of this paper is determine FSFI index at
two specific moments for breast cancer patients – one
month after the diagnosis and just before the second cycle
of chemotherapy, comparing with FSFI index of postme-
nopausal patients on routine gynecological appointments.
We believe that FSFI can be affected by chemotherapy
and the diagnosis of breast cancer is enough by itself to
cause a reduction on FSFI score.
Methods
This cross-sectional, nested cohort study was conducted
at the Hospital de Clínicas de Porto Alegre (HCPA) be-
tween July 2008 and March 2010, after approval by the
local Research Ethics Committee. Nested cohort consist
that patients with breast cancer were followed with FSFI
index applied in two different moments as presented
further.
The primary objective was to assess sexual function by
FSFI in postmenopausal women after diagnosis of breast
cancer and upon completion of one cycle of anthracycline-
based primary chemotherapy (AC regimen, 60/600 mg/m2
IV every 21 days).
The study sample consisted of postmenopausal women
who sought care at the outpatient Gynecology and Breast
Care clinics of Hospital de Clínicas de Porto Alegre
(HCPA), a public university hospital that cares for patients
within the Brazilian Unified Health System framework.
The case group comprised 24 postmenopausal women
with recent diagnosis of breast cancer (treatment-naïvepatients) with primary chemotherapy indication consecu-
tively recruited from the Breast Unit service. The control
group comprised 24 postmenopausal women with no
known malignancy, recruited after presenting for routine
gynecological care at the Obstetrics and Gynecology clinic
that filled FSFI questionnaire. Patients were informed as
to the purpose and objective of the investigation and pro-
vided written informed consent for participation and pub-
lication of the data obtained during the course of the
study.
Inclusion was contingent upon the following criteria:
postmenopausal status, absence of breast cancer, and ab-
sence of current hormone replacement therapy (control
group) or diagnosis of breast cancer with indication for
primary chemotherapy (case group); intellectual capacity
sufficient to ensure understanding of the FSFI instru-
ment; current sexual activity; and clinical performance
status 0–2 considering ECOG levels [adapted from
Zubrod et al. [11]].
The exclusion criteria to both groups were: presence
of any other malignancies, prior diagnosis of psychiatric
disorders, history of diabetes mellitus, vaginal surgery,
hysterectomy or oophorectomy and sexual inactivity.
The Female Sexual Function Index (FSFI) question-
naire was administered to all patients. This instrument,
which has previously been translated into and validated
for Brazilian Portuguese, consists of 19 questions on the
sexual activity performed in the last four weeks. It
enables assessment of six sexual functioning domains:
desire, arousal, lubrication, orgasm, satisfaction, and dis-
comfort/pain [8,9]. Sub-domains are scored considering
the values of each question and its respective conversion
factors and total FSFI Score is the sum of the six results,
ranging from 2 to 36 and better levels of sexual function
are indicated by highest scores.
A demographic questionnaire on family, social, and
educational history was also administered concomitant
with FSFI to all patients in order to collect data on pa-
tient age, educational achievement (of the patient and
her spouse or partner), number of marital partners, use
of prior hormone replacement therapy, and family his-
tory of breast cancer.
In the case group, FSFI was administered 30 days after
the appointment in which patients received the diagnosis
of breast cancer and staging tests were performed during
this period. After initiation of primary chemotherapy,
just before the administration of the second cycle,
patients were again submitted to FSFI questionnaire.
All patients invited to participate agreed to the project
with no loss of follow-up.
Number of patients was determined considering a
variation of 20% loss of FSFI score in the case group
over control group with statistical power of 90% and the
significance level was set at 5% (p≤ 0.05).
Table 1 Sample characteristics
Item Controls Post-diagnosis p
n (%) n (%)
Age* (years) 52.58 ± 7.19 57.29 ± 11.82 0.102†
≤ 55 17 (70.8) 13 (54.2)
> 55 7 (29.2) 11 (45.8)
Educational attainment
Primary education 18 (75) 17 (73.9) 0.839{
Secondary education 4 (16.7) 3 (13.0)
Higher education 2 (8.3) 3 (13.0)
Partner age* (years) 52.54 ±11.88 55.96 ±13.62 0.359†
≤ 55 14 (58.3) 13 (54.2)
> 55 10 (41.7) 10 (41.7)
Partner education
Primary education 15 (65.2) 15 (65.2) 1.000{
Secondary education 6 (26.1) 6 (26.1)
Higher education 2 (8.7) 2 (8.7)
No. partners
One partner 17 (70.8) 13 (54.2) 0.371{
More than one partner 7 (29.2) 11 (45.8)
Family history
Negative - 20 (83.3)
Positive - 4 (16.7)
HRT
No prior therapy - 20 (83.3)
Prior therapy - 4 (16.7)
Clinical stage
IIA–B - 8 (33.3)
IIIA–B - 16 (66.7)
Tumor size
T2 - 8 (33.3)
T3 - 6 (25.0)
T4 - 10 (41.7)
Receptor / HER2/neu status
ER+/PR+/HER2+ - 1 (1.4)
ER+/PR–/ HER2+ - 0 (0)
ER+/PR+/HER2– - 9 (12.5)
ER+/PR–/HER2– - 4 (5.6)
ER–/PR+/HER2+ - 0 (0)
ER–/PR–/HER2+ - 2 (2.8)
ER–/PR+/HER2– - 0 (0)
ER–/PR–/HER2– - 8 (11.1)
Table 1 Sample characteristics (Continued)
Histologic grade
Grade I - 1 (4.2)
Grade II - 17 (70.8)
Grade III - 6 (25.0)
T2 = 2–5 cm; T3 = >5 cm; T4 = inflammatory tumor or invasion of chest wall or
skin.
ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2;
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the Social Sciences) 17.0 software environment (SPSS
Inc., Chicago, IL).
Continuous variables were expressed as mean± standard
deviation (in case of symmetric distribution) or median
and interquartile range (for asymmetric distributions).Categorical variables were expressed as absolute and rela-
tive frequencies.
Student’s t test or the Mann–Whitney U was used for
between-group comparisons of continuous variables.
The Kruskal-Wallis test was used for comparison of edu-
cational achievement, tumor size, hormone receptor sta-
tus, and histological grade.
Categorical variables were compared by means of
Pearson’s chi-square test.
The Wilcoxon test was used for comparison of post-
diagnosis and post-chemotherapy observations in the
case group.
Results
Mean age was 52.58 ± 7.19 years in the control group
and 57.29 ± 11.82 years in the breast cancer group. Mean
spouse or partner age was 52.54 ± 11.88 years and
55.96 ± 13.62 years respectively. Eighty-three percent of
breast cancer patients had no family history of the dis-
ease. Sixteen patients (66.7%) were diagnosed with stage
III and eight (33%) with stage II disease. Educational at-
tainment did not differ significantly between either pa-
tient or partner group (Table 1).
Mean FSFI scores were 23.0 in the control group and
13.5 in the post-diagnosis group. This significant differ-
ence (43% reduction, p < 0.001) was present across all
test domains, and was most substantial in the desire, lu-
brication, and orgasm domains (Table 2).
After one cycle of chemotherapy, FSFI scores declined
to 7.2 from 13.5 – a 46.7% reduction (p = 0.003). Pre and
post-chemotherapy comparisons showed significant
score declines across all domains, with particularly
marked reductions in discomfort/pain and satisfaction
domains (Table 3).
Table 4 shows FSFI score results stratified by demo-
graphic characteristics. Patients over the age of 55
scored worse than younger patients, particularly in the
arousal, lubrication, and pain domains (p = 0.018,
p = 0.030, and p = 0.047 respectively) (Table 5).
Women with lower educational attainment had worse
FSFI scores on diagnosis. Significant differences were
also found in the arousal, lubrication, satisfaction, and
Table 2 Comparison of FSFI scores in post-diagnosis
patients and controls
Domain Controls Post-diagnosis Reduction p*
Median (IQR) Median (IQR)
FSFI (overall) 23.0 (15.0 – 29.3) 13.5 (5.4 – 17.5) 41.3 % <0.001
Desire 3.0 (2.4 – 3.6) 1.2 (1.2 – 4.0) 60.0 % 0.001
Arousal 3.5 (2.7 – 4.2) 1.8 (0.3 – 2.4) 48.6 % <0.001
Lubrication 4.1 (2.5 – 5.4) 1.8 (0.3 – 3.2) 56.1 % 0.003
Orgasm 3.8 (1.3 – 5.1) 1.6 (0.3 – 2.4) 57.9 % 0.003
Satisfaction 4.2 (2.1 – 5.1) 2.2 (1.3 – 3.2) 47.6 % 0.001
Discomfort/Pain 11 (9.0 – 15.0) 8 (0.8 – 10) 27.3 % 0.006
*Mann–Whitney U. IQR, interquartile range.
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p = 0.018 respectively), and were particularly marked
upon comparison to the scores of women with a
secondary-level education (Table 6).
No significant differences were found in partner edu-
cation. Women whose spouses or partners were older
than 55 years, however, had significantly lower FSFI
scores (Table 4).
Stratification of FSFI scores by tumor stage showed
significantly lower scores in patients with more advanced
disease (stages IIIA–B). The most significant differences
were found in the desire and arousal domains (p = 0.004
and p = 0.038 respectively) (Table 7).
There were no statistically significant associations be-
tween FSFI scores considering prior diagnosis, histo-
logical grade, tumor size, or hormone receptor status
(Table 8).
All study participants were sexually active at baseline.
After diagnosis of breast cancer, 25% (n = 6) of case
group had ceased sexual intercourse. This reduction was
statistically significant (p < 0.001). After chemotherapy, a
further five patients had ceased all sexual activity (n = 11,
–45.8%); however, this difference was only borderline
significant on comparison with the post-diagnosis group
(p = 0,063).Table 3 Comparison of post-diagnosis and post-
chemotherapy FSFI scores in breast cancer patients
Domain Post-diagnosis Post-chemotherapy Reduction p*
Median (IQR) Median (IQR)
FSFI (overall) 13.5 (5.4 – 17.5) 7.2 (2.0 – 9.7) 46.7% 0.003
Desire 1.2 (1.2 – 4.0) 1.2 (1.2 – 1.2) 0.0% 0.001
Arousal 1.8 (0.3 – 2.4) 1.2 (0.0 – 1.2) 33.3% <0.001
Lubrication 1.8 (0.3 – 3.2) 1.2 (0.0 – 1.2) 33.3% 0.001
Orgasm 1.6 (0.3 – 2.4) 1.2 (0.0 – 1.2) 25.0% 0.003
Satisfaction 2.2 (1.3 – 3.2) 1.2 (0.8 – 2.3) 45.5% <0.001
Discomfort/Pain 8 (0.8 – 10) 1.2 (0.0 – 1.9) 85.0% <0.001
*Wilcoxon test. IQR, interquartile range.Cessation of sexual activity was statistically associated
with disease stage and tumor size in the post-
chemotherapy group; patients with stage III A–B disease
and/or T4 tumors were more affected than other patients
in terms of new-onset sexual inactivity (Table 9).
Discussion
This study assessed sexual function in postmenopausal
women with breast cancer treated at a large, public uni-
versity hospital in a developing country. FSFI scores
were significantly reduced in women with breast cancer.
In the immediate aftermath of diagnosis, patients already
exhibited significant reductions in total score and across
all FSFI domains as compared to controls. We can ob-
serve that merely receiving a diagnosis of breast malig-
nancy is sufficient to produce a significant reduction on
sexual function, even before patients have received any
form of treatment. Survival-related concerns are highly
influential at the pre-treatment stage and contribute to
this decline in sexual functioning [12].
Administration of one cycle of primary anthracyclin-
based chemotherapy was followed by another significant
reduction in all domains of the FSFI score. The acute
effects of chemotherapy—such as hair loss, weight gain,
pallor, nausea, and vomiting—can make patients feel less
attractive, and adverse effects such as vaginal dryness
and itching contribute to reduced sexual function [13].
Patients over the age of 55 experienced more signifi-
cant reductions in FSFI, as did women whose spouses or
partners were older than 55. Maybe a greater distance
from the borderline age of menopause can destabilize
the couple’s sexual relationship, thus making it prone to
the impact of cancer; however, further data are required
to support this assertion. A diagnosis of cancer can also
rekindle past conflicts between the couple, further con-
tributing to a reduction in sexual function [14].
Although we found no significant association between
reduction in FSFI scores and the prior diagnosis variable
(treatment-naïve patients referred to our breast unit with
clinical diagnosis of breast cancer), patients with
advanced-stage disease experienced more significant
losses in sexual function, particularly in the desire and
arousal domains, which are more susceptible to the dis-
turbances in self-image produced by locally advanced
tumors.
Any discussion of female breast cancer must take into
account not only the factors associated with cancer in
general, but also the aspects related to the social func-
tion of the female body. In the field of symbolism, the
breast plays fundamental roles in female identity, includ-
ing sexuality and sensuality, as an object of pleasure and
desire. A mutilated self-image disrupts the patient’s roles
as spouse and mother and may give rise to feelings of
helplessness, disgust and anguish [15-18].
Table 4 Comparison of FSFI scores according to demographic characteristics
Item Controls Post-diagnosis Post-chemotherapy
Median (IQR) Median (IQR) Median (IQR)
Age (years)
≤ 55 23.7 (15.9 – 29.1)** 15.0 (11.7 – 19.8) 8 (2 – 11.8)**
> 55 20.2 (9.5 – 29.6)* 8.0 (4.2 – 12.9) 2 (2 – 8)**
p† 0.383 0.026 0.063
Educational attainment
Primary education 23.0 (15.4 – 28.4)*** 8.8 (3.1 – 14.6) 7.2 (2.0 – 9.7)***
Secondary education 26.3 (6.8 – 32.8) 21.3 (20.7 – 25.0) 2 (2 – 15.9)
Higher education 21.6 (14.7 – 28.4) 15.0 (7.2 – 17.6) 7.2 (2 – 12.4)
p{ 0.805 0.016 0.889
Partner education
Primary education 21.0 (14.3 – 28.0)** 12.8 (2.0 – 17.1) 2 (2 – 8)**
Secondary education 28.3 (17.2 – 32.1) 16.3 (13.2 – 21.3) 8.9 (5.9 – 13.3)*
Higher education 21.6 (14.7 – 28.4) 10.7 (7.2 – 14.1) 5.8 (2.0 – 9.6)
p{ 0.389 0.129 0.225
Partner age (years)
≤ 55 27.0 (20.3 – 30.1)** 15 (11.7 – 19.8) 8 (2 – 11.8)**
> 55 18.7 (8.5 – 23.4)** 6 (2 – 12.8) 2 (2 – 8)*
p† 0.064 0.001 0.088
No. of partners
One partner 23.7 (15.7 – 30.0)** 12.8 (5.7 – 17.4) 7.2 (2 – 8.8)**
More than one partner 21.0 (14.7 – 27.0) 14.6 (4.8 – 17.6) 7.2 (2 – 11.2)**
p† 0.349 0.608 0.820
*p≤ 0.05, **p≤ 0.01, ***p ≤0.001; vs. post-diagnosis group.
†Mann–Whitney U.
{Kruskal-Wallis test.
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logical, and social well-being of patients, requires adapta-
tion to a new self-image. This, in turn, requires a
supreme effort for which many women are unprepared.
The challenges that arise upon diagnosis deeply unsettle
the inner balance of patients and affect their relation-
ships, making them more prone to conflicts at the per-
sonal and family level [16,19-21].Table 5 Comparison of FSFI domain scores according to
patient age
Domain ≤ 55 years > 55 years p*
Median (IQR) Median (IQR)
Desire 1.8 (1.2 – 2.7) 1.2 (1.2 – 1.8) 0.134
Arousal 2.4 (1.4 – 3.0) 1.2 (0.0 – 1.8) 0.018
Lubrication 3.0 (1.5 – 3.8) 1.2 (0.0 – 1.8) 0.030
Orgasm 2.0 (1.2 – 3.0) 1.2 (0.0 – 2.0) 0.150
Satisfaction 2.4 (1.6 – 3.2) 2.0 (1.2 – 2.8) 0.331
Discomfort/Pain 4.0 (2.6 – 4.8) 1.2 (0.0 – 3.6) 0.047
*Mann–Whitney U.Breast cancer can affect three domains of female sexu-
ality: sexual identity, sexual function, and sexual relations
[16].
Although sexuality is often associated with sexual
intercourse alone, it is far more than that: it is the com-
bined experience of all changes that take place and affect
the manner in which one views oneself and one’s body.
Regardless of age, sexual function is dependent on one’sTable 6 Comparison of FSFI domain scores according to
patient educational attainment
Domain Primary Secondary Higher p*
Median (IQR) Median (IQR) Median (IQR)
Desire 1.2 (1.2 – 2.4) 1.8 (1.2 – 3.6) 2.4 (1.2 – 3.0) 0.454
Arousal 1.5 (0.0 – 2.3)a 3.3 (2.1 – 4.2)b 2.4 (1.2 – 3.0)a,b 0.048
Lubrication 1.2 (0.0 – 3.0)a 4.2 (4.2 – 4.8)b 3.0 (1.2 – 3.6)a,b 0.012
Orgasm 1.2 (0.0 – 2.0)a 4.0 (3.6 – 4.0)b 1.6 (1.2 – 2.0)a,b 0.018
Satisfaction 2.0 (1.0 – 2.6)a 4.4 (3.2 – 4.4)b 1.6 (1.2 – 3.2)a,b 0.035
Discomfort/Pain 2.4 (0.0 – 4.0) 4.8 (4.0 – 5.2) 2.8 (1.2 – 4.0) 0.134
*Kruskal-Wallis test.
a,bSame letters indicate no difference on Mann–Whitney U with an alpha of
0.05.
Table 7 Comparison of FSFI domain scores according to
tumor stage
Domain IIA/B IIIA/B p*
Median (IQR) Median (IQR)
Desire 2.4 (2.0 – 3.0) 1.2 (1.2 – 1.7) 0.004
Arousal 2.4 (1.6 – 3.0) 1.4 (0.0 – 2.1) 0.038
Lubrication 3.0 (2.1 – 3.5) 1.2 (0.0 – 3.1) 0.061
Orgasm 1.8 (1.3 – 2.3) 1.2 (0.0 – 2.7) 0.350
Satisfaction 2.2 (1.6 – 3.2) 2.2 (0.9 – 3.1) 0.490
Discomfort/Pain 4.0 (3.0 – 4.6) 1.8 (0.0 – 3.9) 0.081
*Mann–Whitney U.




II A–B (n=8) 14.8 (14.5 – 19.0)
III A–B (n=16) 8.5 (2.6 – 16.4)
p† 0.052
Tumor size
T2 (n=8) 14.8 (14.5 – 19.0)
T3 (n=6) 10.5 (6.6 – 18.2)
T4 (n=10) 8.5 (2 – 15.6)
p† 0.301
Receptor / HER2/neu status
ER+/PR+/HER2+ (n=1) 8.8 (8.8 – 8.8)
ER+/PR–/ HER2+ (n=0) -
ER+/PR+/HER2– (n=9) 12.8 (5.0 – 14.8)
ER+/PR–/HER2– (n=4) 18.5 (8 – 20.8)
ER–/PR+/HER2+ (n=0) -
ER–/PR–/HER2+ (n=2) 11.4 (2 – 20.7)
ER–/PR+/HER2– (n=0) -
ER–/PR–/HER2– (n=8) 13.5 (5.0 – 18.7)
p{ 0.688
Histologic grade
Grade I (n=1) 15 (15 – 15)
Grade II (n=17) 14.5 (7.6 – 18.5)
Grade III (n=6) 6.5 (2 – 15.8)
p{ 0.362
Prior diagnosis
No (n=19) 14.5 (4.2 – 17.6)
Yes (n=5) 8.8 (7.7 – 17.1)
p† 0.406
T2 = 2–5 cm; T3 = >5 cm; T4 = inflammatory tumor or invasion of chest wall or skin.
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bitual sexual activity [3,20,22].
A diagnosis of cancer is a profoundly stressful event
for patients and their families; all must adapt to the
shock and uncertainty such a diagnosis brings. Patients,
partners, and other family members may be affected by
clinical-level depression and varying levels of anxiety,
fear and other stress reactions [18].
Anticipation of changes in body image may be brought
about by common-knowledge perceptions of the disease,
including the possibility of breast loss or mutilation, hair
loss, pain, and changes in reproductive capacity, as well
as changes in perception of one’s health status, with fear
of death and disease recurrence—compounded by fears
as to the integrity of the intimate relationship and thecteristics
Post-chemotherapy Reduction (%) p*
Median (IQR)
9.8 (7.2 – 12.1) 33.8 0.012
2 (2 – 8) 76.5 0.002
0.016
9.8 (7.2 – 12.1) 33.8 0.012
4.6 (2.0 – 9.1) 56.2 0.028
2 (2 – 8) 76.5 0.028
0.132
8 (8 – 8) 9.1 -
- - -
7.2 (2 – 9.6) 43.8 0.018
6.0 (2 – 11.8) 67.6 0.068
- - -
2 (2 – 2) 82.5 0.317
- - -
5 (2 – 9.7) 63.0 0.018
0.677
7.2 (7.2 – 7.2) 52.0 -
7.2 (2 – 10.6) 50.3 0.001
2 (2 – 8.4) 69.2 0.068
0.489
7.2 (2 – 9.9) 50.3 0.001
2 (2 – 8) 77.3 0.043
0.891
Table 9 Association between tumor stage and size and sexual activity after diagnosis and after chemotherapy











II A – B (n=8) 0 (0.0) 8 (44.4) 0.066 0 (0.0) 8 (61.5) 0.002
III A – B (n=16) 6 (100) 10 (56.6) 11 (100) 5 (38.5)
Tumor size
T2 (n=8) 1 (16.7) 7 (38.9) 0.352 1 (9.1) 7 (53.8)† 0.050
T3 (n=6) 1 (16.7) 5 (27.8) 3 (27.3) 3 (23.1)
T4 (n=10) 4 (66.7) 6 (33.3) 7 (70.0)† 3 (23.1)
*Pearson’s chi-square test or Fisher’s exact test.
†Significant adjusted residuals with alpha = 0.05.
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have a negative impact on the sexual functioning of
patients; even in the general population, depression and
anxiety are associated with increased female sexual dys-
function [18].
Psychosocial support and assessment of quality of life
must be integrated into the treatment and follow-up of
women who receive a diagnosis of breast cancer.
Chemotherapy has already been included as a quality of
life variable in several studies, with some authors con-
cluding it has no long-term impact on quality of life and
others believing it is an important determinant of lower
quality of life in survivors [15,17,23,24].
Time appears to be a determining factor of the in-
fluence of chemotherapy on quality of life after breast
cancer treatment, its impact waning as years go by
[1,7,12].
The adverse effects of breast cancer treatment, such as
fatigue and nausea, must not be neglected. Patients who
receive chemotherapy as part of their treatment regi-
mens are apparently more likely to report severe, persist-
ent fatigue than healthy women, affecting their sexual
performance [22,25,26].Conclusions
The data presented herein attempt to isolate initiation of
chemotherapy and diagnosis as milestones in sexual
function. Future studies may seek a therapeutic ap-
proach capable of minimizing the negative effects of
these events on sexual quality of life and on patients’ in-
timate partners.
There is still much to be observed and researched in
terms of the partner as caregiver and of the partner’s
ability to perceive losses in the woman [27].
Furthermore, health care providers are not properly
trained to understand patient’s complaints or to obtain
an adequate sexual history [28]. This is the key factor
behind current difficulties in assessing sexual quality of
life in cancer patients.By selecting postmenopausal patients, we sought to
exclude a number of variables that interfere with sexual
functioning in premenopausal patients, such as hormo-
nal changes and imminent loss of fertility due to cancer
treatment.
FSFI is an adequate method for quantification of loss
of sexual function in postmenopausal women, although
the scale is unable to provide a satisfactory measure of
the quality of the sexual relationship between subjects
and their partners. Inclusion of only postmenopausal
patients can consist in a limitation of this study, as well
as a weak sexual/psychological analysis of those patients
and their marital history. Our intention was observe and
measure FSFI scores at diagnosis and after the first treat-
ment (chemotherapy). We strongly believe that findings
showed in this paper could stimulate more deep investi-
gations and researches on breast cancer patient’s quality
of life including their sexual problems.
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